Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra
Identifieur interne : 001833 ( Main/Exploration ); précédent : 001832; suivant : 001834Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra
Auteurs : L. Macgillivray [Canada] ; K. B. Reynolds [Canada] ; M. Sickand [Canada] ; P. I. Rosebush [Canada] ; M. F. Mazurek [Canada]Source :
- Synapse [ 0887-4476 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Drugs that selectively inhibit the serotonin transporter (SERT) are widely used in the treatment of depression and anxiety disorders. These agents are associated with a range of extrapyramidal syndromes such as akathisia, dystonia, dyskinesia and parkinsonism, suggesting an effect on dopaminergic transmission. We studied the time course of changes in dopaminergic neurons in the substantia nigra (SN) after initiation of two different SERT inhibitors, citalopram and fluoxetine. In the first experiment, groups of Sprague‐Dawley rats received daily meals of rice pudding either alone (N = 9) or mixed with citalopram 5 mg/kg/day (N = 27). Rats were sacrificed after 24 h, 7 days or 28 days of treatment. Sections of SN were processed for tyrosine hydroxylase (TH) immunohistochemistry. Citalopram induced a significant decrease in TH‐positive cell counts at 24 h (44%), 7 days (38%) and 28 days (33%). No significant differences among the citalopram treatment groups were observed in the SN. To determine whether these changes would occur with other SERT inhibitors, we conducted a second experiment, this time with a 28 day course of fluoxetine. As was observed with citalopram, fluoxetine induced a significant 21% reduction of TH cell counts in the SN. Immunoblot analysis showed that fluoxetine also induced a 45% reduction of striatal TH. To investigate a possible role for the innate immune system in mediating these changes, we also studied the microglial marker OX42 after administration of fluoxetine and noted a significant 63% increase in the SN of fluoxtine‐treated animals. These results indicate that SERT inhibition can activate microglia and alter the regulation of TH, the rate limiting enzyme for dopamine biosynthesis. These changes may play a role in mediating the extrapyramidal side effects associated with SERT inhibitors. Synapse, 2011. © 2011 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/syn.20954
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001250
- to stream Istex, to step Curation: 001250
- to stream Istex, to step Checkpoint: 000418
- to stream Main, to step Merge: 001911
- to stream Main, to step Curation: 001833
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra</title><author><name sortKey="Macgillivray, L" sort="Macgillivray, L" uniqKey="Macgillivray L" first="L." last="Macgillivray">L. Macgillivray</name></author><author><name sortKey="Reynolds, K B" sort="Reynolds, K B" uniqKey="Reynolds K" first="K. B." last="Reynolds">K. B. Reynolds</name></author><author><name sortKey="Sickand, M" sort="Sickand, M" uniqKey="Sickand M" first="M." last="Sickand">M. Sickand</name></author><author><name sortKey="Rosebush, P I" sort="Rosebush, P I" uniqKey="Rosebush P" first="P. I." last="Rosebush">P. I. Rosebush</name></author><author><name sortKey="Mazurek, M F" sort="Mazurek, M F" uniqKey="Mazurek M" first="M. F." last="Mazurek">M. F. Mazurek</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B37A8C432A844C538030714CF5D042E7527F84E5</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/syn.20954</idno><idno type="url">https://api-v5.istex.fr/document/B37A8C432A844C538030714CF5D042E7527F84E5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001250</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001250</idno><idno type="wicri:Area/Istex/Curation">001250</idno><idno type="wicri:Area/Istex/Checkpoint">000418</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000418</idno><idno type="wicri:doubleKey">0887-4476:2011:Macgillivray L:inhibition:of:the</idno><idno type="wicri:Area/Main/Merge">001911</idno><idno type="wicri:Area/Main/Curation">001833</idno><idno type="wicri:Area/Main/Exploration">001833</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra</title><author><name sortKey="Macgillivray, L" sort="Macgillivray, L" uniqKey="Macgillivray L" first="L." last="Macgillivray">L. Macgillivray</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>4U2 Neurology, McMaster University Medical Centre, 1200 Main St W, Hamilton, ON, L8N 3Z5</wicri:regionArea><wicri:noRegion>L8N 3Z5</wicri:noRegion></affiliation></author><author><name sortKey="Reynolds, K B" sort="Reynolds, K B" uniqKey="Reynolds K" first="K. B." last="Reynolds">K. B. Reynolds</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation></author><author><name sortKey="Sickand, M" sort="Sickand, M" uniqKey="Sickand M" first="M." last="Sickand">M. Sickand</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation></author><author><name sortKey="Rosebush, P I" sort="Rosebush, P I" uniqKey="Rosebush P" first="P. I." last="Rosebush">P. I. Rosebush</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation></author><author><name sortKey="Mazurek, M F" sort="Mazurek, M F" uniqKey="Mazurek M" first="M. F." last="Mazurek">M. F. Mazurek</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, 4U, McMaster University Medical Centre, 1200 Main Street W, Hamilton, Ontario L8N3Z5</wicri:regionArea><wicri:noRegion>Ontario L8N3Z5</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">65</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1166">1166</biblScope><biblScope unit="page" to="1172">1172</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">B37A8C432A844C538030714CF5D042E7527F84E5</idno><idno type="DOI">10.1002/syn.20954</idno><idno type="ArticleID">SYN20954</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>citalopram</term><term>fluoxetine</term><term>microglia</term><term>selective serotonin reuptake inhibitor</term><term>serotonin transporter</term><term>tyrosine hydroxylase</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Drugs that selectively inhibit the serotonin transporter (SERT) are widely used in the treatment of depression and anxiety disorders. These agents are associated with a range of extrapyramidal syndromes such as akathisia, dystonia, dyskinesia and parkinsonism, suggesting an effect on dopaminergic transmission. We studied the time course of changes in dopaminergic neurons in the substantia nigra (SN) after initiation of two different SERT inhibitors, citalopram and fluoxetine. In the first experiment, groups of Sprague‐Dawley rats received daily meals of rice pudding either alone (N = 9) or mixed with citalopram 5 mg/kg/day (N = 27). Rats were sacrificed after 24 h, 7 days or 28 days of treatment. Sections of SN were processed for tyrosine hydroxylase (TH) immunohistochemistry. Citalopram induced a significant decrease in TH‐positive cell counts at 24 h (44%), 7 days (38%) and 28 days (33%). No significant differences among the citalopram treatment groups were observed in the SN. To determine whether these changes would occur with other SERT inhibitors, we conducted a second experiment, this time with a 28 day course of fluoxetine. As was observed with citalopram, fluoxetine induced a significant 21% reduction of TH cell counts in the SN. Immunoblot analysis showed that fluoxetine also induced a 45% reduction of striatal TH. To investigate a possible role for the innate immune system in mediating these changes, we also studied the microglial marker OX42 after administration of fluoxetine and noted a significant 63% increase in the SN of fluoxtine‐treated animals. These results indicate that SERT inhibition can activate microglia and alter the regulation of TH, the rate limiting enzyme for dopamine biosynthesis. These changes may play a role in mediating the extrapyramidal side effects associated with SERT inhibitors. Synapse, 2011. © 2011 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Macgillivray, L" sort="Macgillivray, L" uniqKey="Macgillivray L" first="L." last="Macgillivray">L. Macgillivray</name></noRegion><name sortKey="Macgillivray, L" sort="Macgillivray, L" uniqKey="Macgillivray L" first="L." last="Macgillivray">L. Macgillivray</name><name sortKey="Macgillivray, L" sort="Macgillivray, L" uniqKey="Macgillivray L" first="L." last="Macgillivray">L. Macgillivray</name><name sortKey="Mazurek, M F" sort="Mazurek, M F" uniqKey="Mazurek M" first="M. F." last="Mazurek">M. F. Mazurek</name><name sortKey="Mazurek, M F" sort="Mazurek, M F" uniqKey="Mazurek M" first="M. F." last="Mazurek">M. F. Mazurek</name><name sortKey="Reynolds, K B" sort="Reynolds, K B" uniqKey="Reynolds K" first="K. B." last="Reynolds">K. B. Reynolds</name><name sortKey="Reynolds, K B" sort="Reynolds, K B" uniqKey="Reynolds K" first="K. B." last="Reynolds">K. B. Reynolds</name><name sortKey="Rosebush, P I" sort="Rosebush, P I" uniqKey="Rosebush P" first="P. I." last="Rosebush">P. I. Rosebush</name><name sortKey="Sickand, M" sort="Sickand, M" uniqKey="Sickand M" first="M." last="Sickand">M. Sickand</name><name sortKey="Sickand, M" sort="Sickand, M" uniqKey="Sickand M" first="M." last="Sickand">M. Sickand</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001833 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001833 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B37A8C432A844C538030714CF5D042E7527F84E5
|texte= Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra
}}
| This area was generated with Dilib version V0.6.29. |  |